Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 8/20 | 0.46 |
| ▸ | RARB | P10826 | 8/20 | 0.46 |
| ▸ | RARG | P13631 | 8/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848764 | 0.86 | RARA (0.37) | RARARARBRARGRXRACYP3A4 | |
| SCHEMBL30714187 | 0.81 | RARA (0.43) | RARARARBRARGRXRAKDM1A | |
| SCHEMBL3492816 | 0.81 | RARA (0.43) | RARARARBRARGRXRAKDM1A | |
| SCHEMBL8293245 | 0.80 | RARA (0.47) | RARARARBRARGRXRACYP3A4 | |
| SCHEMBL9009692 | 0.80 | RARA (0.36) | RARARARBRARGRXRACYP3A4 | |
| SCHEMBL9054284 | 0.79 | RARA (0.46) | RARARARBRARGRXRACYP3A4 | |
| SCHEMBL9188112 | 0.79 | RARA (0.49) | RARARARBRARGRXRACYP3A4 | |
| SCHEMBL8081648 | 0.79 | RARA (0.46) | RARARARBRARGRXRACYP3A4 | |
| SCHEMBL13708653 | 0.79 | RARA (0.46) | RARARARBRARGRXRACYP3A4 | |
| SCHEMBL7657399 | 0.78 | KDM1A (0.34) | RARARARBRARGRXRAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | claimed |
| US-20060205950-A1 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2006-09-14 | — | — | US | claimed |
| EP-1700855-A1 | A process for the preparation of tazarotene | SOLMAG S.p.A. (IT) | 2006-09-13 | — | — | EP | claimed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| WO-2015107542-A2 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| US-5519150-A | Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates | ALLERGAN (US) | 1996-05-21 | — | — | US | disclosed |
| EP-0405028-B1 | Thiochroman esters of phenols and terephthalates having retinoid-like activity | ALLERGAN INC (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1995019973-A2 | PROCESS FOR PREPARING 4,4-DIALKYL-6-HALO-CHROMANS OR THIOCHROMANS USEFUL AS PHARMACEUTICAL INTERMEDIATES | ALLERGAN (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0661258-A1 | Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
| US-5420295-A | Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates | ALLERGAN, INC. (US) | 1995-05-30 | — | — | US | disclosed |
| US-5015658-A | Treatment of skin disorders such as psoriasis | ALLERGAN, INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0405028-A1 | Thiochroman esters of phenols and terephthalates having retinoid-like activity | ALLERGAN, INC (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4895868-A | PSORIASIS, SKIN DISORDERS, ANTIARTHRITIC, WOUND HEALING, EYE DRYNESS | ALLERGAN, INC. (US) | 1990-01-23 | — | — | US | disclosed |
| US-4829080-A | SKIN DISORDERS, PSORIASIS, ACNE | L'OREAL (FR) | 1989-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205950-A1 | Process for the preparation of Tazarotene | DHPS, COASY, STS | RARA 1663/4885RARB 1324/4885RARG 1550/4885 |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | PPIA, CUTA, TFPI | RARA 77/4885RARB 130/4885RARG 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.